Saint Jean De Verges

Researchers are evaluating the effects of the probiotic B. lactis B94 on infants diagnosed with infantile colic. This randomized, double-blind, placebo-controlled Phase 2 study aims to determine whether the probiotic can reduce the duration of daily crying compared to a placebo after 4 weeks of treatment. Infantile colic is characterized by prolonged periods of crying or fussiness, and this study seeks to explore a potential dietary intervention to ease these symptoms. Participants will be randomly assigned to one of two groups: one receiving a daily sachet of the probiotic B. lactis B94, and the other receiving a placebo. Both treatments are taken once daily, dissolved in 10 ml of lukewarm water, and administered at approximately the same time each day. The study spans 6 weeks, including a 1-week baseline period, a 4-week intervention period, and a 1-week follow-up. During this time, families will attend three in-person visits and participate in four phone calls to support adherence and monitoring. Throughout the study, parents will maintain questionnaires, records, and diaries related to their infant's symptoms. Researchers will track changes in daily crying duration as the primary outcome over 4 weeks. The study also involves clinical assessments during visits and telephone follow-ups to ensure safety and collect data. Participation requires exclusive breastfeeding and commitment to study procedures over the full 6-week period.

Researchers are studying patients who have metastatic lung cancer and have survived for more than three years after their diagnosis without receiving cytotoxic chemotherapy. The focus is on understanding their clinical features, health status, quality of life, and socio-economic impacts, including the effects of cancer treatments, the occurrence of new diseases, and return to work. This observational study aims to better identify the needs of these long-term survivors to improve their management. Participants will complete several questionnaires, including the Hospital Anxiety and Depression Scale (HAD), the Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13), and the Aix-Marseille-University (AMU) questionnaire. These are designed to assess anxiety, depression, lung cancer symptoms, treatment side effects, and overall quality of life. Questionnaires are completed at the start of the study, at 6 and 12 months, and then yearly for up to 5 years. Participants will be followed during their regular medical consultations as per usual care at participating centers. Throughout the study, researchers will collect information on clinical characteristics, treatment details, health status, socio-demographic factors, and quality of life measures. Data will be gathered at baseline and during follow-up visits up to 5 years. This information will help assess the long-term impact of lung cancer and its treatments on patients who are living well beyond initial expectations.